Revance Therapeu Stock Price, News & Analysis

Revance Therapeutics (RVNC) reported significant revenue growth in Q4 2021, achieving $26.0 million, up from $11.1 million in Q4 2020, driven by strong sales of the RHA® Collection of dermal fillers. Full-year revenue reached $77.8 million. The company completed critical drug substance manufacturing for the FDA's BLA resubmission of DaxibotulinumtoxinA for Injection. Cash reserves totaled $225.1 million. However, the net loss for 2021 was substantial at $281.3 million. The company anticipates 2022 operating expenses between $375 million to $400 million, maintaining an optimistic outlook for growth and product approvals.

Revance Therapeutics will release its Q4 and full year 2021 financial results on February 28, 2022 after market close. A conference call and live webcast will occur at 4:30 p.m. ET to discuss results and provide a business update. Revance is focused on innovative aesthetic and therapeutic products with a strong pipeline, including DaxibotulinumtoxinA, currently seeking U.S. regulatory approval for glabellar lines and cervical dystonia. They also hold exclusive U.S. rights to the RHA® Collection of dermal fillers.

Revance Therapeutics (NASDAQ: RVNC) announced that it received Type A meeting minutes from the FDA concerning the Complete Response Letter (CRL) for DaxibotulinumtoxinA for Injection. A requalification of the new working cell bank (WCB) is required, which involves producing three drug substance lots and one drug product lot. The FDA mandates a reinspection of Revance’s facility once the resubmission is accepted, which could take up to 6 months. The CEO expressed confidence in a clear path for BLA resubmission.

Revance Therapeutics (RVNC) reported preliminary Q4 2021 RHA® Collection revenue between $23.0 million and $24.0 million, bringing full-year revenue to approximately $70.0 million to $71.0 million. Cash, cash equivalents, and short-term investments stood at about $225 million as of December 31. The company expects its operating expenses for the year to be at the lower end or below earlier guidance of $375 million to $390 million. Revance held a Type A meeting with the FDA regarding DaxibotulinumtoxinA for Injection.

Revance Therapeutics (NASDAQ: RVNC) presented new data on DaxibotulinumtoxinA for Injection at the ASDS Virtual Annual Meeting from November 19-21, 2021. Highlights include findings from the SAKURA Phase 3 trials, which assessed immunogenicity and treatment for glabellar lines. An innovative injection technique for midface volumization using hyaluronic acid fillers was also discussed. The presentations underscore Revance's commitment to setting new standards in facial aesthetics and its robust growth pipeline.

Revance Therapeutics (NASDAQ: RVNC) announces CEO Mark Foley and CFO Tobin Schilke will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. This event will stream online starting November 22 in the investor relations section of Revance’s website. The conference runs from November 30 to December 2, 2021. Revance focuses on innovative aesthetic and therapeutic solutions, including DaxibotulinumtoxinA for Injection, which is seeking U.S. regulatory approval after completing Phase 3 trials.

Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17. CEO Mark Foley is set to present on November 17 at 8:20 a.m. CT. Interested parties can access the live audio webcast via the company's Investor Relations page. Revance specializes in innovative aesthetic and therapeutic products, including its neuromodulator DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials for glabellar lines and is pursuing U.S. regulatory approval.

Revance Therapeutics (RVNC) reported Q3 2021 revenue of $19.7 million, a substantial increase from $3.8 million in Q3 2020, primarily driven by the RHA® Collection of dermal fillers, which generated $18.3 million this quarter. The net loss decreased to $74.4 million from $81.3 million year-over-year. The company plans to request a Type A meeting with the FDA to address deficiencies in its BLA for DaxibotulinumtoxinA for Injection for glabellar lines. Additionally, positive results from the ASPEN-OLS Phase 3 study for cervical dystonia were announced, showing the product's long-term safety and effectiveness.

Revance Therapeutics, Inc. (NASDAQ: RVNC) will announce its third quarter 2021 financial results on November 9, 2021, after market close. A conference call and live webcast will occur at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and offer a business and pipeline update. Revance focuses on innovative aesthetic and therapeutic products, including the next-generation neuromodulator DaxibotulinumtoxinA for Injection, aiming for U.S. regulatory approval. The company also partners with Viatris to develop a biosimilar to BOTOX®.